Tech Company Financing Transactions
Finch Therapeutics Funding Round
Avenir Growth Capital, Morgan Noble Healthcare Partners and Shumway Capital participated in a $36 million Series B funding round for Finch Therapeutics. The financing round closed on 3/3/2018.
Transaction Overview
Company Name
Announced On
3/3/2018
Transaction Type
Venture Equity
Amount
$36,000,000
Round
Series B
Investors
Proceeds Purpose
Financing to support ongoing Phase 2 study of CP101 in recurrent C. difficile infection and advance pipeline of earlier stage products.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
200 Inner Belt Rd. 400
Somerville, MA 02143
USA
Somerville, MA 02143
USA
Phone
Website
Email Address
Overview
Finch Therapeutics Group is a clinical-stage biopharmaceutical company focused on developing and delivering innovative microbial therapies.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Mark Smith
Chief Financial Officer
Gregory Perry
Chief Medical Officer
Zain Kassam
Chief Operating Officer
Andrew Noh
Vice President
James Burgess
Vice President
Irina Koroleva
Vice President
David Rhodes
Vice President
Martina Schinke
VP - Bus. Development
James Sigler
VP - General Counsel
Ben Enerson
VP - Operations
Anne Conway
VP - R & D
Sonia Timberlake
VP - Regulatory Affairs
Kris Piper
VP - Regulatory Affairs
Rozanna Yaing
Browse more venture capital transactions:
Prev: 3/3/2018: Woebot venture capital transaction
Next: 3/3/2018: PlumCare venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs